Potent and selective Src tyrosine kinase family inhibitor; anticancer; antiviral; orally bioavailable
Saracatinib is a potent and selective Src tyrosine kinase family inhibitor (IC50 = 4-10 nM). Inhibits Src, c-Yes, Fyn, Lyn, Blk, Fgr, and Lck. Exhibits selectivity over other tyrosine kinases (IC50 values are 30, 66 and 200 nM for v-Abl, EGFR and c-Kit, respectively). Suppresses invasion of HT1080 cells through a collagen matrix and inhibits metastasis in a murine model of bladder cancer. Inhibits the growth of prostate cancer cell lines. Also suppresses MERS-CoV replication at the early stage of replication (EC50 = 2.9 μM) and displays broad-spectrum activity against other human coronaviruses. Also blocks dengue virus RNA replication. Reverses memory deficit in a mouse AD model and rescues synapse density. Inhibits osteoclast activity, resorption and formation. Induces autophagy. Orally bioavailable.
| Marque | Tocris |
|---|---|
| Réf. B-LABO | BL-RE-125108 |
| Réf. fabricant | 18726546 |
| Nom chimique ou matériau | N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2 H-pyran-4-yl)oxy]-4-quinazolinamine |
| CAS | 379231-04-6 |
| Quantité | 50 mg |
| Cible | Src Family Kinase Inhibitors |
| Formule moléculaire | C<sub>27</sub>H<sub>32</sub>ClN<sub>5</sub>O<sub>5</sub> |
| Pureté | 0.98 |
